Skip to content

Selatogrel Outcome Study in suspected Acute Myocardial Infarction (SOS-AMI)

SOS-AMI is a global phase 3 research study for people who have experienced one or more heart attacks and are at risk of experiencing heart attack(s) again in the future.

The study will assess whether an investigational drug called selatogrel can treat a heart attack when self-administered by participants using a study autoinjector.

All participants in the SOS-AMI study will receive training on how and when to use the study autoinjector, as well as regular follow-ups with the study team.

null

Participation Requirements

  • Sex:

    Female, Male

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:
- Male or female ≥ 18 years old
- Diagnosed of type 1 AMI within 4 weeks prior to randomization
- Additional risk factors
- Successful placebo self-injection
Exclusion Criteria:
- Increased risks of serious bleeding
- Chronic hematological conditions
- Diseases/conditions not compatible with study participation
- Life threatening disease

Study Location

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Jen Le

null
780-613-5007
Study Sponsored By
University of Alberta
Participants Required
More Information
Study ID: Pro00116679